---
id: ags-beers-criteria-2023
title: "AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults"
short_title: "AGS Beers Criteria 2023"

organization: American Geriatrics Society
collaborators: null
country: US
url: https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.18372
doi: 10.1111/jgs.18372
pmid: 37139824
open_access: false

specialty: geriatrics
guideline_type: clinical-practice
evidence_system: null
conditions:
  - potentially inappropriate medications
  - PIMs
  - geriatrics
tags:
  - anticholinergics
  - benzodiazepines
  - deprescribing
  - medication safety

publication_date: 2023-05-01
previous_version_date: 2019-01-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-22
---

## Scope
Evidence-based list of potentially inappropriate medications (PIMs) for adults ≥65 years, intended to reduce adverse drug events in older adults across all care settings (except hospice/end-of-life).

## Key Categories

### Category 1: Medications to Avoid in Most Older Adults

#### Anticholinergics
| Drug Class | Examples | Rationale |
|------------|----------|-----------|
| First-generation antihistamines | Diphenhydramine, chlorpheniramine, hydroxyzine | Highly anticholinergic; cognitive impairment, delirium |
| Antispasmodics | Dicyclomine, hyoscyamine | Anticholinergic effects |
| Antiparkinsonians | Benztropine, trihexyphenidyl | Anticholinergic; alternatives available |

#### CNS Active Drugs
| Drug Class | Examples | Rationale |
|------------|----------|-----------|
| Benzodiazepines | Diazepam, lorazepam, alprazolam | Falls, fractures, cognitive impairment |
| Non-benzodiazepine hypnotics ("Z-drugs") | Zolpidem, eszopiclone, zaleplon | Similar risks to benzodiazepines |
| Barbiturates | Phenobarbital (except for seizures) | High risk of physical dependence |
| Antipsychotics | All (except for schizophrenia, bipolar, delirium) | Stroke risk, mortality in dementia |

#### Cardiovascular
| Drug | Rationale |
|------|-----------|
| Alpha-1 blockers (for hypertension) | Orthostatic hypotension |
| Central alpha-agonists (clonidine, methyldopa) | CNS effects, orthostatic hypotension |
| Digoxin >0.125 mg/day | Toxicity risk in renal impairment |
| Nifedipine (immediate-release) | Hypotension risk |

#### Gastrointestinal
| Drug Class | Examples | Rationale |
|------------|----------|-----------|
| PPIs (long-term >8 weeks) | Omeprazole, pantoprazole | C. diff, fractures, B12 deficiency |
| Metoclopramide | All | Extrapyramidal effects, tardive dyskinesia |

#### Pain Medications
| Drug Class | Examples | Rationale |
|------------|----------|-----------|
| Meperidine | Demerol | Neurotoxic metabolite, seizures |
| Non-COX-selective NSAIDs (chronic use) | Ibuprofen, naproxen | GI bleeding, renal impairment, CV risk |
| Indomethacin | - | Highest CNS adverse effects of NSAIDs |
| Skeletal muscle relaxants | Carisoprodol, cyclobenzaprine, methocarbamol | Anticholinergic effects, sedation |

### Category 2: Medications to Avoid with Specific Diseases/Syndromes

| Condition | Avoid | Rationale |
|-----------|-------|-----------|
| Heart failure | NSAIDs, thiazolidinediones, diltiazem, verapamil (if HFrEF) | Fluid retention, worsening HF |
| Dementia/Cognitive impairment | Anticholinergics, benzodiazepines, antipsychotics | Worsen cognition, increase mortality |
| Falls/Fractures | Benzodiazepines, Z-drugs, antipsychotics, opioids | Increase fall risk |
| Parkinson's disease | Metoclopramide, all antipsychotics (except quetiapine, pimavanserin) | Worsen parkinsonism |
| Chronic kidney disease (CKD) | NSAIDs, lithium | Nephrotoxicity |
| Urinary incontinence | Alpha-blockers (females), antimuscarinics (for urge incontinence with cognitive impairment) | Worsen incontinence or cognition |

### Category 3: Medications to Use with Caution

| Drug/Class | Concern |
|------------|---------|
| Aspirin for primary prevention | Bleeding risk may exceed benefit in ≥70 years |
| Dabigatran | Increased GI bleeding vs. warfarin in ≥75 years |
| Prasugrel | Increased bleeding in ≥75 years |
| SSRIs/SNRIs | SIADH, falls |
| Diuretics | Electrolyte disturbances, falls |

### Category 4: Drug-Drug Interactions to Avoid

| Combination | Risk |
|-------------|------|
| ≥3 CNS-active drugs | Falls, fractures, delirium |
| Opioid + gabapentinoid | Severe sedation, respiratory depression |
| Opioid + benzodiazepine | Severe sedation, respiratory depression |
| Warfarin + NSAIDs | Major bleeding |
| ACEi/ARB + K-sparing diuretic + NSAID | Acute kidney injury |

## Key Principles
- Not a prohibition list—clinical judgment essential
- Consider safer alternatives when available
- Deprescribing is a valid strategy
- Apply across all settings (ambulatory, acute, long-term care)
- Does not apply to hospice/end-of-life care
